PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Total Equity

Last Annual Value

147.44M

3-Year CAGR

-6%

5-Year CAGR

72%

10-Year CAGR

44%

PepGen Inc.

PepGen Inc. Competitors Analysis of Total Equity

PEPG · NASDAQ
CompanyTotal Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
147.44M
10.8%2.1%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
30.65M
-38.9%-36.7%N/A
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
312.32M
4.6%4.5%N/A
57.01M
N/A-1.8%N/A
7.92M
N/AN/AN/A
151.14M
N/AN/AN/A
256.59M
1.4%-8.0%N/A
18.41M
14.7%N/AN/A
113.87M
-20.4%-27.2%N/A
74.40M
-18.5%-21.8%14.8%
147.50M
N/A16.4%32.4%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642